Tempus AI has made a significant investment in Personalis through multiple transactions on August 16, 2024. The company purchased 3.5 million shares of Personalis common stock at $5.07 per share, totaling $17.7 million. Additionally, Tempus exercised previously issued warrants to acquire 9.2 million shares at exercise prices of $1.50 and $2.50 per share, for an aggregate purchase price of $18.4 million.The companies also amended their Commercialization and Reference Laboratory Agreement, extending the termination notice period to 30 months. The amendment includes enhanced obligations for Personalis regarding potential assignments to competitors and commitments to maintain increased laboratory capacity for new patients. Personalis agreed to register the resale of the newly purchased shares within 30 days.

Tempus AI has made a significant investment in Personalis through multiple transactions on August 16, 2024. The company purchased 3.5 million shares of Personalis common stock at $5.07 per share, totaling $17.7 million. Additionally, Tempus exercised previously issued warrants to acquire 9.2 million shares at exercise prices of $1.50 and $2.50 per share, for an aggregate purchase price of $18.4 million.The companies also amended their Commercialization and Reference Laboratory Agreement, extending the termination notice period to 30 months. The amendment includes enhanced obligations for Personalis regarding potential assignments to competitors and commitments to maintain increased laboratory capacity for new patients. Personalis agreed to register the resale of the newly purchased shares within 30 days.